Integrative analysis of multi-platform reverse-phase protein array data for the pharmacodynamic assessment of response to targeted therapies

Autor: Vonick Sibut, Stephan Bernhardt, Leanne de Koning, Bérengère Ouine, Ulrike Korf, Neil O. Carragher, Bryan Serrels, Kenneth G. MacLeod, Aurélie Cartier, Adam Byron

Publikováno v: Scientific Reports, Vol 10, Iss 1, Pp 1-12 (2020)
Scientific Reports
Byron, A, Bernhardt, S, Ouine, B, Cartier, A, Macleod, K G, Carragher, N O, Sibut, V, Korf, U, Serrels, B & Koning, L D 2020, ' Integrative analysis of multi-platform reverse-phase protein array data for the pharmacodynamic assessment of response to targeted therapies ', Scientific Reports, vol. 10, no. 1, 21985, pp. 1-12 . https://doi.org/10.1038/s41598-020-77335-0
Byron, A, Bernhardt, S, Ouine, B, Cartier, A, Macleod, K, Carragher, N O, Sibut, V, Korf, U, Serrels, B & de Koning, L 2020, ' Integrative analysis of multi-platform reverse-phase protein array data for the pharmacodynamic assessment of response to targeted therapies ', Scientific Reports . https://doi.org/10.1038/s41598-020-77335-0

Reverse-phase protein array (RPPA) technology uses panels of high-specificity antibodies to measure proteins and protein post-translational modifications in cells and tissues. The approach offers sensitive and precise quantification of large numbers

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0bcd575568c59b911f4eef0f2aabd44
https://doaj.org/article/07e3b471ccaf448185223b213fb7f35a

Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition

Autor: Aurélie Cartier, Paul Cottu, Rania El Botty, Florence Coussy, Sophie Chateau-Joubert, Rana Hatem, Leanne de Koning, Elisabetta Marangoni, Jean-Luc Servely, Sophie Vacher, Bérengère Ouine, Sophie Leboucher, Ivan Bièche, Franck Assayag, Charles Fouillade

Publikováno v: Oncotarget

Breast cancer is a complex disease in which each patient could present several genetic alterations that are therapeutically relevant in cancers. Here we explored the therapeutic benefit of combining PARP and mTOR inhibitors in a context of DNA repair

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42e168a2d02c0af41691945ee2b4366c
https://doi.org/10.18632/oncotarget.25640

PARP Inhibition Increases the Response to Chemotherapy in Uveal Melanoma

Autor: Pascale Mariani, André Nicolas, Leanne De Koning, Aurélie Cartier, Vesselina G. Cooke, Sergio Roman-Roman, Andrew Wylie, Didier Decaudin, Rania El Botty, Adnan Naguez, Fariba Nemati, Nathalie Cassoux, Justine Fleury, Didier Meseure, Guillaume Carita, Paul Smith, Sophie Piperno-Neumann, Elisabetta Marangoni, Mathieu Schuller, David Gentien, Bérengère Ouine

Publikováno v: Cancers
Volume 11
Issue 6
Cancers, Vol 11, Iss 6, p 751 (2019)

Uveal melanoma (UM) remains without effective therapy at the metastatic stage, which is associated with BAP-1 (BRCA1 associated protein) mutations. However, no data on DNA repair capacities in UM are available. Here, we use UM patient-derived xenogra

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f7ba6667d81d4d3c23662e8528d0dad
http://europepmc.org/articles/PMC6628115

Correction: Protein biomarkers predictive for response to anti-EGFR treatment in RAS wild-type metastatic colorectal carcinoma

Autor: Astrid Lièvre, Bérèngere Ouine, Jim Canet, Aurélie Cartier, Yael Amar, Wulfran Cacheux, Odette Mariani, Rosine Guimbaud, Janick Selves, Thierry Lecomte, Serge Guyetant, Ivan Bieche, Frédérique Berger, Leanne de Koning

Publikováno v: British Journal of Cancer

Metastatic colorectal cancer (mCRC) patients with mutant KRAS or NRAS are ineligible for anti-epidermal growth factor receptor (anti-EGFR) therapy, as RAS mutations activate downstream pathways independently of EGFR and induce primary resistance. How

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fd351ea0cea4bbd4b8184391f4a9a5a8
http://europepmc.org/articles/PMC6079395

Abstract 1853: Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer when combined to PARP inhibition

Autor: Rania El Botty, Leanne De Koning, Marine Huppé, Franck Assayag, Elisabetta Marangoni, Ahmed Dahmani, Aurélie Cartier, Florence Coussy, Jean Luc Servely, Paul Cottu, Ivan Bièche, Rana Hatem, Berangere Ouine, Sophie Chateau Joubert, Sophie Vacher, Virginie Bernard

Publikováno v: Cancer Research. 77:1853-1853

Purpose: DNA repair deficiencies and activation of PI3K/AKT/mTOR pathway are common events in breast cancer. BRCA1/2 mutations have been associated with sensitivity to PARP1 inhibitors (synthetic lethality), while alterations in component of the PI3K

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3dbcc49fb28359981e3a7463f5dc62ec
https://doi.org/10.1158/1538-7445.am2017-1853